Information  X 
Enter a valid email address

Summit Corporation (SUMM)

  Print      Mail a friend

Wednesday 16 January, 2008

Summit Corporation

Start of Ph II clinical trial

Summit Corporation PLC
16 January 2008



Summit Corporation plc
('Summit plc' or 'the Company')


SUMMIT PLC'S LEAD DRUG CANDIDATE ENTERS PHASE II CLINICAL TRIALS
Candidate targets sialorrhoea, a symptom of Parkinson's disease


Oxford, UK, 16 January 2008 - Summit Corporation plc (AIM: SUMM), a leading UK
biotechnology company, announces that is has started a Phase II proof of concept
clinical trial of its small molecule drug candidate SMT D001 for the treatment
of sialorrhoea.

Sialorrhoea is a common and distressing symptom of Parkinson's disease
characterised by the overproduction of saliva and uncontrollable drooling. This
condition is also a symptom of several other diseases including cerebral palsy,
stroke, muscular dystrophy and oesophageal cancer.  The estimated treatable
population within the major pharmaceutical markets (US, EU, Japan, Canada and
Australia) is in excess of three million patients.


The Phase II clinical trial is:

•  A randomised, double-blind, placebo-controlled trial being conducted
   in the United Kingdom;

•  Being conducted in a total of 40 Parkinson's patients; patients will
   be treated in cohorts of ten and dosed over ten-week periods; and,

•  Aiming to establish proof of concept for SMT D001 as a combination therapy 
   with a reduction in saliva secretion rates being measured as the primary
   end point for the trial.


Summit has received approval to commence the trial from the UK's Medicines and
Healthcare products Regulatory Agency (MHRA) and has begun the patient
recruitment process. The Company expects to announce first results from this
clinical trial in Q3 of 2008 after completing dosing in all 40 patients.
Additional trials to investigate and optimise the formulation of SMT D001 will
follow on from this current trial.  Results from an earlier Phase I study
conducted in nine healthy volunteers demonstrated saliva suppression levels of
up to 40%.

SMT D001 has been developed using Summit's drug re-profiling expertise and is a
combination therapy designed to reduce saliva production that exploits the
well-known side-effects of two off-patent drugs with an established history of
safe use.  In additional to SMT D001, Summit has a second re-profiled,
early-stage clinical programme targeting the symptoms of Parkinson's disease.
SMT D002 is being developed as a novel treatment for seborrhoea (excessive sebum
production).  Seborrhoea is also believed to be the primary cause of acne and
SMT D002 is currently in a Phase I clinical trial with the results expected
during Q1 2008.

Steven Lee, PhD, Chief Executive Officer of Summit, said 'Drug re-profiling
programmes such as SMT D001 provide the opportunity to identify and develop
novel indications for known drugs in a quick and cost-effective manner.  The
start of this Phase II clinical trial and the progress being made by SMT D002 is
adding further to the value of both these programmes as Summit actively seeks to
sign attractive commercial licensing deals.'



                                    - ENDS -


For more information, please contact:

Summit plc

Steven Lee, PhD, Chief Executive Officer               Tel: +44 (0)1235 443951
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations


Citigate Dewe Rogerson

Mark Swallow, PhD / David Dible                        Tel: +44 (0)207 638 9571


Panmure Gordon

Andrew Burnett / Rakesh Sharma                         Tel: +44 (0)207 459 3600




About Summit plc

Summit plc is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced carbohydrate chemistry and drug screening (chemical
genomics) technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

Summit plc has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.

Summit plc's in-house drug development capabilities combine world-class
expertise in both carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: SUMM

Further information about the company is available at www.summitplc.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange